title: Prevention of esophageal variceal rebleeding.
abstract: The rate of rebleeding of esophageal varices remains high after cessation of acute esophageal variceal hemorrhage. Many measures have been developed to prevent the occurrence of rebleeding. When considering their effectiveness in reduction of rebleeding, the associated complications cannot be neglected. Due to unavoidable high incidence of complications, shunt surgery and endoscopic injection sclerotherapy are now rarely used. Transjugular intrahepatic portosystemic stent shunt was developed to replace shunt operation but is now reserved for rescue therapy. Nonselective beta-blockers alone or in combination with isosorbide mononitrate and endoscopic variceal ligation are currently the first choices in the prevention of variceal rebleeding. The combination of nonselective beta-blockers and endoscopic variceal ligation appear to enhance the efficacy. With the advent of newly developed measures, esophageal variceal rebleeding could be greatly reduced and the survival of cirrhotics with bleeding esophageal varices could thereby be prolonged.
authors.affiliation: Division of Gastroenterology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, and National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C. ghlo@isca.vghks.gov.tw
authors.forename: Gin-Ho
authors.initials: GH
authors.lastname: Lo
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D004932:Esophageal and Gastric Varices / Q000628:therapy*; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control*; D006801:Humans; D008026:Ligation; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D012008:Recurrence; D015911:Sclerotherapy
chemical_list: D000319:Adrenergic beta-Antagonists